Dyne Therapeutics, Inc. DYN
Institutional shares held
148 Million
184K
calls
243K
puts
Total value of holdings
$2.8B
$3.47M
calls
$4.57M
puts
Market Cap
$975M
51,765,400
Shares Out.
Institutional ownership
286.73%
# of Institutions
227
We take great care to ensure that the data presented and summarized in this overview for Dyne Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DYN
View all-
Janus Henderson Group PLC London, X014.7MShares$278 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.76MShares$184 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$172 Million26.07% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$139 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$103 Million13.81% of portfolio
-
State Street Corp Boston, MA5.27MShares$99.3 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY4.73MShares$89.1 Million2.34% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.62MShares$86.9 Million6.54% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.55MShares$67 Million0.08% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.41MShares$64.3 Million0.01% of portfolio
Latest Institutional Activity in DYN
Top Purchases
Top Sells
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Transactions at DYN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
2,662
-1.33%
|
$53,240
$20.72 P/Share
|
|
Dec 05
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
144
-0.15%
|
$2,880
$20.72 P/Share
|
|
Dec 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
880
-1.0%
|
$17,600
$20.72 P/Share
|
|
Sep 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
2,640
-1.31%
|
$34,320
$13.41 P/Share
|
|
Sep 05
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
144
-0.15%
|
$1,872
$13.41 P/Share
|
|
Sep 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
873
-0.98%
|
$11,349
$13.41 P/Share
|
|
Sep 04
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
894
-0.93%
|
$11,622
$13.27 P/Share
|
|
Sep 04
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,552
-3.83%
|
$46,176
$13.27 P/Share
|
|
Jul 15
2025
|
John Cox CEO & President |
SELL
Bona fide gift
|
Direct |
40,000
-4.41%
|
-
|
|
Jul 14
2025
|
John Cox CEO & President |
BUY
Open market or private purchase
|
Direct |
100,000
+29.22%
|
$900,000
$9.11 P/Share
|
|
Jun 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,342
-1.43%
|
$17,446
$13.35 P/Share
|
|
Jun 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
4,060
-2.78%
|
$52,780
$13.35 P/Share
|
|
Jun 05
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
146
-0.15%
|
$1,898
$13.35 P/Share
|
|
Mar 31
2025
|
Erick Lucera Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,100
+50.0%
|
-
|
|
Mar 13
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
143
-0.15%
|
$1,716
$12.12 P/Share
|
|
Mar 11
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,153
-1.09%
|
$23,683
$11.38 P/Share
|
|
Mar 11
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,343
-1.09%
|
$14,773
$11.38 P/Share
|
|
Mar 05
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
917
-0.74%
|
$10,087
$11.83 P/Share
|
|
Mar 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
4,061
-2.7%
|
$44,671
$11.83 P/Share
|
|
Mar 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,343
-1.41%
|
$14,773
$11.83 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.28M
Shares
From
3
Insiders
| Grant, award, or other acquisition | 1.18M shares |
|---|---|
| Open market or private purchase | 100K shares |
Sell / Disposition
77.3K
Shares
From
6
Insiders
| Open market or private sale | 37.3K shares |
|---|---|
| Bona fide gift | 40K shares |